AKNE-MYCIN
LOE ApproachingNDATOPICALOINTMENT
Approved
Jan 1985
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 14h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AKNE-MYCIN is a topical ointment approved in 1985 for acne treatment, representing a legacy dermatology product in Bausch + Lomb's portfolio. The drug's mechanism of action and generic name are not publicly disclosed in available data, limiting assessment of its pharmacological positioning.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100), indicating a contracting brand team and defensive commercial posture.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on AKNE-MYCIN offers limited career growth opportunities given its LOE-approaching lifecycle and zero linked job postings. Professionals on this brand should expect focus on margin protection, generic transition planning, and potential role consolidation within Bausch + Lomb's dermatology franchise.
Brand ManagerField Sales Representative
Worked on AKNE-MYCIN at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.